Validogen — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Validogen is a Vienna-based biotech CRO founded in 2017, focused on advanced protein production using its exclusive UNLOCK PICHIA® yeast expression platform. The company provides a full suite of strain and process development services to a diverse clientele, from startups to large industry players, aiming to solve challenging protein production problems. Its technology features proprietary promoters, secretion signals, and high-throughput screening to maximize yields, with a proven track record of enabling products for clinical studies and commercial markets. Validogen operates as a private, service-driven company, generating revenue through contracted R&D projects.

BiologicsAntibodies

Technology Platform

UNLOCK PICHIA®: A proprietary Pichia pastoris (Komagataella phaffii) protein expression toolbox featuring methanol-inducible and methanol-free promoters, platform strains (including ARM-free options), novel secretion signals, expression-enhancing helper factors, glycoprotein engineering tools, and predictive high-throughput screening capabilities.

Opportunities

Growing demand for outsourced biologics development and complex protein production creates a expanding market for its specialized services.

The shift towards safer, methanol-free expression systems and regulatory preference for ARM-free strains aligns perfectly with its platform capabilities.

Successful delivery of proteins into clinical trials and commercial markets serves as powerful validation to attract new clients across therapeutics and industrial enzymes.

Risk Factors

Revenue is project-based and variable, susceptible to biotech funding cycles and client concentration.

Faces intense competition from other CROs/CDMOs and alternative expression technologies.

Its business model typically grants no ownership of end-products, capping financial upside from client successes, and execution risks during scale-up could damage its reputation.

Competitive Landscape

Validogen competes in a fragmented market against large, diversified CDMOs offering yeast expression services, other specialized microbial expression CROs, and in-house development teams at biopharma companies. Its key differentiation is its deep, exclusive focus on the Pichia pastoris platform, a high-throughput screening-driven approach, and a toolbox enabling methanol-free and ARM-free production, which may not be matched by generalist competitors.

More companies in Proteomics & Protein Engineering →More companies in Austria →